Prognostic Value of Pretreated Blood Inflammatory Markers in Patients with Bone Sarcoma: A Meta-Analysis

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2021 Apr 26

PMID 33897913

Citations 6

Authors

Min Jiang

Shaowei Ma

Zhongyan Hua

Zhiying Zhao

Song Gao

Affiliations

Soon will be listed here.

Abstract

Method: We conducted a detailed literature search in Medline and Embase databases and collected relevant publications written in English before April 2020. Overall survival (OS) and disease-free survival (DFS) were the primary and secondary outcomes, respectively. Basic features of patients, hazard ratios (HRs), and 95% confidence intervals (CI) were retrieved to assess the correlation between pretreated blood inflammatory markers and patients with bone sarcoma. This meta-analysis used Stata 12.0.

Results: A total of 10 studies containing 1845 cases were included for analysis. Nine of them evaluated the neutrophil lymphocyte ratio (NLR), 7 the platelet lymphocyte ratio (PLR), and 4 the lymphocyte monocyte ratio (LMR). Pooled results revealed that higher pretreatment NLR was associated with poorer OS (HR = 1.76, 95% CI: 1.29-2.41, and < 0.001) and DFS (HR = 1.77, 95% CI: 1.09-2.88, and = 0.021). In contrast, a lower LMR was related to worse OS (HR = 0.73, 95% CI: 0.57-0.92, and = 0.009), but not DFS (HR = 0.68, 95% CI: 0.41-1.11, and > 0.05). Combined results did not show a significant predictive effect of PLR on the clinical outcomes of patients with bone sarcoma (OS : HR = 1.32, 95% CI: 0.99-1.75, and > 0.05; DFS: HR = 1.12, 95% CI: 0.87-1.44, > 0.05).

Conclusion: NLR and LMR might be promising predictive biomarkers for patients with bone sarcoma and could be used to stratify patients and provide personalized therapeutic strategies.

Citing Articles

Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data.

Gurruchaga Sotes I, Gomez-Mateo M, Ortega Izquierdo M, Martinez-Trufero J Cancers (Basel). 2024; 16(2).

PMID: 38254758 PMC: 10813902. DOI: 10.3390/cancers16020267.

A new model of preoperative systemic inflammatory markers predicting overall survival of osteosarcoma: a multicenter retrospective study.

Huang X, Liu Y, Liang W, Luo K, Qin Y, Li F BMC Cancer. 2022; 22(1):1370.

PMID: 36585638 PMC: 9805258. DOI: 10.1186/s12885-022-10477-8.

Inflammatory Surrogate Parameters for Predicting Ifosfamide-Induced Neurotoxicity in Sarcoma Patients.

Schmidt M, Benzler K, Lauer U, Zender L, Hinterleitner C, Hinterleitner M J Clin Med. 2022; 11(19).

PMID: 36233666 PMC: 9572151. DOI: 10.3390/jcm11195798.

Three-Dimension-Printed Custom-Made Prosthetic Reconstructions in Bone Tumors: A Single Center Experience.

Vitiello R, Matrangolo M, El Motassime A, Perna A, Cianni L, Maccauro G Curr Oncol. 2022; 29(7):4566-4577.

PMID: 35877221 PMC: 9322169. DOI: 10.3390/curroncol29070361.

Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions.

Zak K, Zaremba B, Rajtak A, Kotarski J, Amant F, Bobinski M Cancers (Basel). 2022; 14(8).

PMID: 35454875 PMC: 9029111. DOI: 10.3390/cancers14081966.

References

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Su X, Teng J, Jin G, Li J, Zhao Z, Cao X . ELK1-induced upregulation of long non-coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2. Biomed Pharmacother. 2018; 109:788-797. DOI: 10.1016/j.biopha.2018.10.029. View

Aggerholm-Pedersen N, Maretty-Kongstad K, Keller J, Baerentzen S, Safwat A . The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma. Transl Oncol. 2016; 9(4):322-8. PMC: 5006814. DOI: 10.1016/j.tranon.2016.05.006. View

Park J, Fuglestad A, Kostner A, Oliwa A, Graham J, Horgan P . Systemic Inflammation and Outcome in 2295 Patients with Stage I-III Colorectal Cancer from Scotland and Norway: First Results from the ScotScan Colorectal Cancer Group. Ann Surg Oncol. 2020; 27(8):2784-2794. PMC: 7334267. DOI: 10.1245/s10434-020-08268-1. View

Hui J . Epidemiology and Etiology of Sarcomas. Surg Clin North Am. 2016; 96(5):901-14. DOI: 10.1016/j.suc.2016.05.005. View

Huang X, Hu H, Zhang W, Shao Z . Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma. J Cell Physiol. 2019; 234(10):18408-18414. DOI: 10.1002/jcp.28476. View

Liang Y, Wang W, Que Y, Guan Y, Xiao W, Fang C . Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma. BMC Cancer. 2018; 18(1):942. PMC: 6169079. DOI: 10.1186/s12885-018-4856-x. View

Li Y, Liu X, Zhang J, Yao W . Prognostic role of elevated preoperative systemic inflammatory markers in localized soft tissue sarcoma. Cancer Biomark. 2016; 16(3):333-42. DOI: 10.3233/CBM-160571. View

Galdiero M, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S . Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013; 218(11):1402-10. DOI: 10.1016/j.imbio.2013.06.003. View

10.

Li Y, Yang X, Zhang W, Yi C, Wang F, Li P . Clinical implications of six inflammatory biomarkers as prognostic indicators in Ewing sarcoma. Cancer Manag Res. 2017; 9:443-451. PMC: 5628701. DOI: 10.2147/CMAR.S146827. View

11.

Shen Y, Wang H, Chen X, Li W, Chen J . Prognostic significance of lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization and radiofrequency ablation. Onco Targets Ther. 2019; 12:7129-7137. PMC: 6731523. DOI: 10.2147/OTT.S217935. View

12.

Jaillon S, Galdiero M, Del Prete D, Cassatella M, Garlanda C, Mantovani A . Neutrophils in innate and adaptive immunity. Semin Immunopathol. 2013; 35(4):377-94. DOI: 10.1007/s00281-013-0374-8. View

13.

Yang Q, Chen T, Yao Z, Zhang X . Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma. World J Surg Oncol. 2020; 18(1):24. PMC: 6993441. DOI: 10.1186/s12957-020-1789-z. View

14.

Li L, Bai Z, Zhang L, Zhang Y, Lu X, Zhang Y . Meta-Analysis of Hematological Biomarkers as Reliable Indicators of Soft Tissue Sarcoma Prognosis. Front Oncol. 2020; 10:30. PMC: 7002470. DOI: 10.3389/fonc.2020.00030. View

15.

Wang J, Hui Z, Men Y, Kang J, Sun X, Deng L . Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2019; 108(6):1701-1709. DOI: 10.1016/j.athoracsur.2019.06.035. View

16.

Liu M, Yang P, Mao G, Deng J, Peng G, Ning X . Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis. Int J Surg. 2019; 72:206-213. DOI: 10.1016/j.ijsu.2019.11.004. View

17.

Liu B, Huang Y, Sun Y, Zhang J, Yao Y, Shen Z . Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci Rep. 2016; 6:39862. PMC: 5180218. DOI: 10.1038/srep39862. View

18.

Wojtukiewicz M, Sierko E, Hempel D, Tucker S, Honn K . Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev. 2017; 36(2):249-262. PMC: 5557865. DOI: 10.1007/s10555-017-9673-1. View

19.

Hoffmann T, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson J . Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002; 8(8):2553-62. View

20.

Papale M, Buccarelli M, Mollinari C, Russo M, Pallini R, Ricci-Vitiani L . Hypoxia, Inflammation and Necrosis as Determinants of Glioblastoma Cancer Stem Cells Progression. Int J Mol Sci. 2020; 21(8). PMC: 7215563. DOI: 10.3390/ijms21082660. View